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Objectives This study determined whether greater 2-year declines in Walking Impairment Questionnaire (WIQ) stair climb-
ing, distance, or speed scores were associated with higher all-cause and cardiovascular disease (CVD) mortality
among men and women with lower extremity peripheral artery disease (PAD).
Background Associations of decline in the WIQ with mortality among people with PAD are unknown.
Methods Participants were 442 men and women with PAD identified from Chicago area medical centers. The WIQ was
completed at baseline and at 2-year follow-up. Cox proportional hazard models were used to assess associations
across categories of 2-year changes in WIQ stair climbing, WIQ distance, and WIQ speed scores with subsequent
all-cause and CVD mortality, adjusting for age, sex, race, ankle-brachial index, body mass index, smoking, co-
morbidities, and other covariates.
Results One hundred twenty-three participants (27.8%) died during a median follow-up of 4.7 years after the 2-year change in
WIQ score measurements. Forty-five participants died from CVD. Adjusting for covariates, participants with WIQ score
declines 20.0 points had higher all-cause mortality (hazard ratio [HR]: 1.93, 95% confidence interval [CI]: 1.01 to
3.68 for WIQ stair climbing; HR: 2.34, 95% CI: 1.15 to 4.75 for WIQ distance; and HR: 3.55, 95% CI: 1.57 to 8.04 for
WIQ speed, respectively) compared with participants with 20.0 point improvement in each of the corresponding
WIQ categories. Participants with 20.0 point declines in the WIQ distance score had higher CVD mortality (HR: 4.56,
95% CI: 1.30 to 16.01) compared with those with 20.0 point improvement in the WIQ distance score.
Conclusions Patients with PAD who experienced 20.0 point declines in the WIQ stair climbing, distance, and speed scores
had a higher rate of all-cause mortality compared with those with less declines in each WIQ score. (J Am Coll
Cardiol 2013;61:1820–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.060Lower extremity peripheral artery disease (PAD) affects
more than 8 million Americans (1). Compared with those
without PAD, people with PAD are at higher risk for
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accepted January 24, 2013.all-cause and cardiovascular mortality (2). The Walking
Impairment Questionnaire (WIQ) is a PAD-specific, self-
administered questionnaire that measures patient-perceived
difficulty climbing stairs and walking specific distances and
speeds (3). We previously reported that lower baseline
values for the WIQ stair climbing scores were associated
with higher all-cause and cardiovascular disease (CVD)
mortality in PAD (4). In the present study, we assessed
whether greater declines in WIQ stair climbing, distance,
and speed scores are associated with higher all-cause and
CVD mortality among patients with PAD. We measured
2-year change in the WIQ scores because assessing change
over 2 years allowed greater opportunity to identify a
significant decline in the WIQ, and because patients with
PAD are commonly followed longitudinally in clinical
practice for 2 years or more. We hypothesized that greater
declines in each WIQ score would be associated with higher
all-cause and CVD mortality. In exploratory analyses, we
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WIQ scores with higher mortality were attenuated by
adjustment for progression of PAD and other CVD.
Methods
Participant identification. Participants for this analysis were
identified from the WALCS (Walking and Leg Circulation
Study) and WALCS II studies (Fig. 1). The WALCS and
WALCS II are prospective, observational studies designed to
identify clinical characteristics associated with functional impair-
ment, functional decline, and mortality in PAD (5,6). The
WALCS cohort of 460 participants was assembled from
October 1998 to March 2000. The WALCS II cohort of
489 participants with PAD was assembled from November
2002 to April 2004. WALCS II included WALCS partic-
ipants who consented to participation in WALCS II as well
as newly identified participants (Fig. 1). WALCS partici-
pants were followed for up to 8 years, whereas newly
identified participants for WALCS II were followed for up
to 4 years. WALCS participants were ages 55 years and
older at the time of enrollment. PAD participants newly
identified for WALCS II 4 years later were ages 59 years
and older at enrollment. For both WALCS and WALCS
II, PAD participants were identified consecutively from
among patients diagnosed with PAD in 3 Chicago area
noninvasive vascular laboratories. This method ensured a
systematic method of enrollment and minimized bias. We
did not collect data on the duration of the PAD diagnosis.
Onset of PAD is difficult to ascertain accurately because
PAD is frequently asymptomatic (5). The institutional
review boards of Northwestern University and collaborating
sites approved the study protocol. Written informed consent
was obtained from all participants.
Exclusion criteria. We excluded participants with an
ankle-brachial index (ABI) 0.90 at baseline because they
either did not have PAD or because they had noncompress-
ible arteries, which did not allow accurate assessment of
PAD severity. At enrollment for WALCS and WALCS II,
participants with above- or below-knee amputations or
ulcers, nursing home residents, and wheelchair-bound pa-
tients were excluded due to severely limited functional
capacity at baseline. We did not systematically exclude
participants with critical limb ischemia. Non–English-
speaking participants were excluded because data collection
forms, including the WIQs, were prepared only in English.
At baseline, participants with recent major surgery and
self-identified or physician-identified dementia, as well as
those unlikely to return for 12-month follow-up because of
medical illness or logistical issues were excluded.
Walking Impairment Questionnaire. Participants com-
pleted the WIQ at baseline and at 2-year follow-up. In the
WIQ distance score, the participant records the degree of
difficulty walking specific distances (ranging from walking
indoors to 1,500 feet or 5 blocks) on a graded scale from 0
to 4 (3). A score of 0 represents the inability to walk thedistance in question and a score
of 4 represents no difficulty. In
the WIQ speed score, the partic-
ipant is asked to assess the degree
of difficulty walking 1 block at
specific speeds ranging from
walking slowly to jogging on a
graded scale ranging from 0 to 4
(3). In the WIQ stair climbing
score, the participant reports the
degree of difficulty climbing 1, 2,
and 3 flights of stairs. This
graded score is multiplied by a
pre-specified weight for each dis-
tance, speed, or number of stair
flights. The products are summed
and divided by the maximum
possible score to obtain a percent score, ranging from 0
(representing the inability to perform any of the tasks) to
100 (representing no difficult with any of the tasks) (7). The
WIQ scores have been shown to improve in response to
lower extremity revascularization (8) and supervised exercise
therapy (9).
Ankle-brachial index measurement. Using a handheld
Doppler probe (Nicolet Vascular Pocket Dop II, Nicolet
Biomedical, Golden, Colorado), systolic pressures were
measured in the right and left brachial, posterior tibial, and
dorsalis pedis arteries, and then again in reverse order. The
ABI was calculated by dividing the mean of the posterior
tibial and dorsalis pedis pressures in each leg by the mean of
the 4 brachial pressures (10). Average brachial pressures in
the arm with highest pressure were used when 1 brachial
pressure was higher than the opposite brachial pressure in
both measurement sets and the 2 brachial pressures differed
by 10 mm Hg or more in at least 1 measurement set,
because subclavian stenosis was possible in such cases (11).
The lowest leg ABI was used in analyses.
Comorbidities. At baseline, we measured presence of co-
morbidities that could potentially influence both the WIQ
scores and mortality: history of congestive heart failure,
angina, myocardial infarction (MI), stroke, diabetes, cancer,
and chronic pulmonary disease. Verification of comorbidi-
ties was performed using algorithms developed for the
Women’s Health and Aging Study (12), which combines
data from medical record review, medications, patient self-
report, selected laboratory values, and a questionnaire com-
pleted by the participant’s primary care provider. We used
similar methods to identify new stroke, MI, and angina that
were diagnosed after baseline.
Physical activity. At baseline, participant-reported physi-
cal activity was measured with a questionnaire derived from
the Harvard Alumni Activity Study that has been validated
in participants with PAD (13). Participants were asked the
following question: “During the last week, how many city
blocks or their equivalent did you walk? Let 12 city blocks
Abbreviations
and Acronyms
ABI  ankle-brachial index
ACE  angiotensin-
converting enzyme
BMI  body mass index
CVD  cardiovascular
disease
MI  myocardial infarction
PAD  peripheral arterial
disease
PCS  physical component
summary
WIQ  Walking Impairment
Questionnaireequal 1 mile.”
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measured, and body mass index (BMI) was calculated.
Cigarette smoking history was self-reported. Participants
brought in their medication bottles or a list of medica-
tions to their baseline study visit. A study investigator
(M.M.M.), blinded to other patient characteristics, iden-
tified use of angiotensin-converting enzyme (ACE) in-
hibitor medications or statins from the list of participant
medications.
Death. Information on deaths was obtained from proxies,
the Social Security Administration death database, and
primary care providers. Death certificate information from
Figure 1 PAD Participants Eligible for Analyses
The cohort composition based on eligibility and data availability for peripheral arte
and WALCS II studies. WIQ  Walking Impairment Questionnaire.the state in which the death occurred, family members, orfrom the participants’ medical records was also obtained.
Deaths from CVD were those with International Classifi-
cation of Diseases-10th Revision codes in the range I00.0
through I99. This included deaths due to stroke, peripheral
vascular disease, coronary heart disease, heart failure, and
sudden cardiac death. A certified nosologist, blinded to
participant characteristics, adjudicated cause of death based
on the death certificate.
Statistical analyses. Change in each WIQ score (stair
climbing, distance, and speed score) was calculated as the
difference between the 2-year follow-up WIQ score and the
corresponding baseline WIQ domain score. Participants
ease (PAD) participants in the Walking and Leg Circulation Study (WALCS)rial diswere excluded from analyses if they died or underwent lower
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if their WIQ score data were missing at either visit (Fig. 1).
For each WIQ score domain, baseline characteristics of
participants across 5 categories of WIQ score change were
compared using linear models for continuous variables and
logistic models for categorical variables. We defined 5
categories of WIQ score change in an a priori fashion after
examining the distribution of change in each WIQ score
between baseline and 2-year follow-up. We aimed to define
categories that resulted in relatively similar numbers of
participants in each category and also represented incre-
ments of 5-point change that could be more easily remem-
bered by clinicians. In addition, the 5 categories were
defined because they resulted in a nearly symmetric distri-
bution of WIQ change scores. Category 1 consisted of
participants whose WIQ score declined by 20.0 points
(worst). Category 2 consisted of participants whose WIQ
score declined by 20.0 points and 5.0 points. Category
3 included participants whose WIQ score declined by 5.0
points, but did not increase by 5.0 points. Category 4
included participants whose WIQ score increased by 5.0
points and 20.0 points, and Category 5 included partici-
pants whose WIQ score increased by 20.0 points (best).
Cox proportional hazards analyses were used to compare
differences in all-cause and CVD mortality across categories
of 2-year WIQ score change, with Category 5 (best) for
each WIQ domain used as the reference. Pairwise p values
were calculated between the lower 4 (worst) categories and
highest (best) category. Overall p for trend was also calcu-
lated. Analyses adjusted for baseline age, sex, race, ABI,
BMI, current smoking, comorbidities, ACE inhibitor use,
study cohort (WALCS vs. WALCS II), statin use, baseline
WIQ score, and physical activity. We also assessed the
association of the mean change in all 3 WIQ scores
combined with all-cause and CVD mortality.
To assess whether the progression of systemic CVD
mediated associations of 2-year decline in WIQ domain
scores with mortality, additional exploratory analyses were
performed, which added adjustment for change in ABI,
incident stroke, incident MI, and incident angina from
baseline to 2-year follow-up.
In additional analyses, we used Cox proportional
hazards analyses to determine whether greater 2-year
decline in WIQ scores was associated with greater 2-year
decline in the ABI, adjusting for age, sex, race, BMI,
baseline ABI, smoking, physical activity, comorbidities,
medication use, baseline WIQ score, and study cohort.
We also performed multivariable logistic regression anal-
yses to identify clinical characteristics associated with
Category 1 (i.e., decline in WIQ of 20 points). Finally,
we calculated the degree to which the addition of each
WIQ change score to a statistical model of traditional
mortality risk factors in PAD improved the model’s
predictive ability for mortality.Results
Baseline characteristics. Of 1,142 participants who com-
pleted baseline testing for WALCS and WALCS II, 700
had PAD (Fig. 1). Of these, 64 who died and 43 who
underwent lower extremity revascularization between base-
line and 2-year follow-up were excluded. Ninety-six PAD
participants missing WIQ score data at 2-year follow-up
and 8 participants missing covariate data were excluded,
leaving 442 participants available for analyses. Of 442
participants included in the analyses, 123 (27.8%) partici-
pants died during a median follow-up of 56.5 months
(interquartile range: 27.1 to 74.9 months) after the 2-year
change in WIQ scores was assessed. Of these, 45 deaths
(36.6%) were attributed to CVD. The cause of death was
unknown in 11 decedents. Median follow-up for CVD
mortality was 44.7 months (interquartile range: 24.9 to 73.0
months).
Table 1 lists the baseline characteristics of participants
according to the degree of change in each WIQ domain
score. The lowest (worst) category for 2-year change in
WIQ stair climbing score was associated with older age.
The lowest (worst) category for 2-year change in WIQ
distance score was associated with higher physical activity at
baseline. Mean 2-year changes in WIQ stair climbing,
distance, and speed scores were 0.79, 1.78, and 1.55,
respectively.
In multivariable logistic regression, higher baseline phys-
ical activity, measured by blocks walked in the past week,
was associated with greater decline in the WIQ distance and
speed scores, respectively (data not shown). History of
cancer was also associated with greater decline in the WIQ
speed score, and older age and history of hip arthritis were
associated with greater declines in the WIQ stair climbing
score (data not shown).
Associations of 2-year change in WIQ scores with all-
cause and CVD mortality. Tables 2 to 4 show associations
of 2-year change in each WIQ score with all-cause and
CVD mortality, adjusting for baseline age, sex, race, ABI,
BMI, smoking status, comorbidities, statin use, ACE in-
hibitor use, study cohort, physical activity, and baseline
WIQ domain score.
Greater 2-year decline in WIQ stair climbing score was
associated with higher all-cause mortality (p for trend 
0.004) (Table 2). After additional adjustment for any newly
diagnosed stroke, MI, or angina, or progression in the ABI,
the association of greater 2-year decline in WIQ stair
climbing score with higher all-cause mortality was attenu-
ated and remained statistically significant only in the model
that additionally adjusted for change in ABI. No significant
association was observed between greater 2-year decline in
WIQ stair climbing score and higher CVD mortality.
Greater 2-year decline in WIQ distance score was asso-
ciated with higher all-cause mortality (p for trend  0.006)
(Table 3). After additional adjustment for any newly diag-
nosed stroke, MI, or angina, or progression in the ABI, the
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with higher all-cause mortality was attenuated and no
longer statistically significant. Overall, no significant asso-
ciations were observed between greater 2-year decline in
WIQ distance score and higher CVD mortality. However,
participants in Category 1 (worst) and Category 2 for 2-year
change in WIQ distance score had a higher incidence of CVD
mortality compared with participants in Category 5 (best) for
2-year change in WIQ distance score (hazard ratio [HR]: 4.56,
95% confidence interval [CI]: 1.30 to 16.01; and HR: 4.31,
95% CI: 1.26 to 14.80, respectively). After adjustment for
2-year change in ABI, participants in Category 1 (worst) for
Baseline Characteristics of Peripheral Arterial Disease ParticipantsAccording to 2-Year Change in WIQ Sco e by Categories of ChangeTable 1 B seline Charact ristics of P pheral Art ri l DiseasAccording to 2-Year Change in WIQ Score by Categorie
Change in WIQ
Category 1
Decline >20.0 Points
(n  84)
Category 2
Decline 20.0–5.0
Points (n  78)
Age, yrs 74.74 8.04 71.37 8.75
Male, % 66.67 51.28
Black race, % 10.71 24.36
ABI 0.64 0.14 0.64 0.14
BMI, kg/m2 28.34 4.90 27.76 5.72
Current smoker, % 16.67 17.95
Angina, % 39.29 20.51
CHF, % 22.62 14.10
MI, % 28.57 15.38
Stroke, % 10.71 12.82
Pulmonary disease, % 30.95 32.05
Cancer, % 14.29 16.67
Diabetes, % 39.29 30.77
Blocks walked in the past
week, n
33.11 36.33 35.81 69.35
Statin use, % 55.95 46.15
ACE inhibitor use, % 36.90 19.23
Change in W
Category 1
Decline >20.0 Points
(n  88)
Category 2
Decline 20.0–5.0
Points (n  69)
Age, yrs 72.19 8.09 73.75 7.12
Male, % 65.91 43.48
Black race, % 13.64 17.39
ABI 0.69 0.12 0.64 0.15
BMI, kg/m2 27.96 4.38 27.70 5.03
Current smoker, % 17.05 24.64
Angina, % 39.77 31.88
CHF, % 25.00 18.84
MI, % 26.14 23.19
Stroke, % 13.64 8.70
Pulmonary disease, % 30.68 39.13
Cancer, % 12.50 10.14
Diabetes, % 35.23 33.33
Blocks walked in the past
week, n
52.41 76.50 30.71 37.31
Statin use, % 52.27 46.38
ACE inhibitor use, % 34.09 24.642-year change in WIQ distance score were at greater risk forCVD mortality compared with participants in Category 5
(best) for 2-year change in WIQ distance score (p  0.036).
Greater decline in the WIQ speed score was associated with
higher all-cause mortality (p for trend  0.019) (Table 4).
After additional adjustment for any newly diagnosed stroke,
MI, or angina, or progression in the ABI, the association of
greater 2-year decline in WIQ speed score with higher
all-cause mortality was attenuated and no longer statistically
significant. However, participants in Category 1 (worst) and
Category 2 for 2-year change in WIQ speed score remained
at higher risk for all-cause mortality compared with partic-
ipants in Category 5 (best) after adjusting for change in the
442)icipants
Change (n  442)
limbing Score
Category 3
ne <5.0 and Increase
.0 Points (n  130)
Category 4
Increase 5.0–20.0
Points (n  66)
Category 5
Increase >20.0
Points (n  80)
p for
Trend
73.48 8.07 71.91 8.82 71.54 7.80 0.04
44.62 68.18 61.25 0.36
12.31 13.64 17.50 0.21
0.65 0.15 0.67 0.15 0.67 0.15 0.24
28.24 5.15 27.11 3.93 27.33 4.76 0.59
15.38 16.67 20.00 0.81
32.31 42.42 21.25 0.31
24.62 25.76 13.75 0.97
24.62 22.73 27.50 0.22
13.08 7.58 16.25 0.55
37.69 36.36 27.50 0.87
15.38 10.61 21.25 0.40
27.69 31.82 28.75 0.51
17.93 40.75 37.58 47.31 39.48 58.44 0.65
43.08 40.91 36.25 0.08
28.46 27.27 22.50 0.06
tance Score
Category 3
ne <5.0 and Increase
.0 Points (n  129)
Category 4
Increase 5.0–20.0
Points (n  77)
Category 5
Increase >20.0
Points (n  68)
p for
Trend
73.31 8.59 72.34 8.09 71.15 8.85 0.38
56.59 62.34 54.41 0.52
13.18 11.69 20.59 0.54
0.64 0.14 0.65 0.17 0.66 0.16 0.26
28.09 5.24 27.76 4.36 27.86 5.86 0.88
13.18 12.99 22.06 0.68
31.01 24.68 25.00 0.05
19.38 20.78 16.18 0.10
22.48 24.68 22.06 0.88
10.85 10.39 16.18 0.73
37.98 25.97 30.88 0.76
17.83 20.78 14.71 0.75
27.91 28.57 35.29 0.87
25.94 39.59 33.00 35.10 31.99 51.67 0.01
44.19 41.56 35.29 0.08
25.58 28.57 20.59 0.06
Continued on the next page(n Part
s of
Stair C
Decli
<5
IQ Dis
Decli
<5ABI (p  0.013). No association was observed between
W ACE 
ire.
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mortality.
When each WIQ change score was added to a traditional
risk model predicting all-cause and cardiovascular mortality,
the change score generally modestly improved the predictive
ability of the overall model. Specifically, for all-cause mor-
tality, the improvements in prediction were 0.02,0.075,
and0.046 for the WIQ distance, speed, and stair climbing
scores, respectively, on a scale of 2.0 to 2.0 scale, where
2.0 represents the greatest possible gain in prediction and
2.0 represents the greatest possible loss of prediction
ability. For CVD mortality, the improvements in prediction
were 0.080, 0.071, and 0.005 for the WIQ distance,
speed, and stair climbing scores, respectively, on the scale of
2.0 to 2.0.
Greater decline in the average of the 3 WIQ score
domains was associated with increased mortality, adjusting
for age, sex, race, ABI, BMI, smoking status, comorbidities,
statin use, ACE inhibitor use, study cohort, physical activ-
ity, and baseline WIQ domain score (p trend  0.004).
Associations of each category of average WIQ score decline
with all-cause mortality were: Category I, HR: 3.91 (95%
CI: 1.75 to 8.78); Category 2, HR: 1.88 (95% CI: 0.93 to
3.81); Category 3, HR: 1.25 (95% CI: 0.62 to 2.54); and
Category 4, HR: 1.42 (95% CI: 0.65 to 3.12) relative to the
reference of Category 5. Greater decline in the averaged
WIQ score was not associated with increased CVD mor-
tality (p trend  0.0545).
Greater declines in WIQ score were not associated with
ContinuedTable 1 Continued
Change in W
Category 1
Decline >20.0 Points
(n  77)
Category 2
Decline 20.0–5.0
Points (n  121)
Age, yrs 71.79 9.05 72.76 8.45
Male, % 66.23 51.61
Black race, % 16.88 12.90
ABI 0.67 0.12 0.66 0.14
BMI, kg/m2 27.32 4.49 28.52 5.55
Current smoker, % 16.88 17.20
Angina, % 31.17 38.71
CHF, % 16.88 21.51
MI, % 23.38 22.58
Stroke,% 7.79 17.20
Pulmonary disease, % 32.47 44.09
Cancer, % 20.78 16.13
Diabetes,% 31.17 29.03
Blocks walked in the past
week, n
51.92 75.48 30.08 43.85
Statin use, % 45.45 56.99
ACE inhibitor use, % 27.27 30.11
Values shown are mean SE, unless otherwise indicated. Where applicable, values are the means
IQ domain score from the baseline respective WIQ domain score. ABI  ankle brachial index;
myocardial infarction; PAD  peripheral arterial disease; WIQ  Walking Impairment Questionnagreater ABI declines, adjusting for age, sex, race, comor-bidities, BMI, baseline ABI, baseline WIQ score, physical
activity, or medications (data not shown).
Discussion
Among 442 men and women with PAD, greater 2-year
declines in WIQ stair climbing, distance, and speed scores
were associated with higher all-cause mortality, after adjust-
ing for baseline ABI, baseline WIQ score, comorbidities,
age, and other potential confounders. Participants with
20.0 point declines in WIQ stair climbing, WIQ distance,
and WIQ speed scores had approximately 2- to 3-fold
increases in all-cause mortality compared with those with
20.0 point increases in these scores. In addition, partici-
pants with a 20.0 point decline in WIQ distance score
were nearly 4 times more likely to die from CVD compared
with those with a20.0 point increase in the WIQ distance
score. Because our analyses adjusted for baseline WIQ score,
these results demonstrated meaningful associations of
change in each WIQ domain score, even after taking into
account the baseline WIQ score.
We did not observe a significant association between
greater 2-year declines in WIQ stair climbing, distance,
and speed scores with higher CVD mortality. Given the
relatively low number of deaths due to CVD, statistical
power was limited for the association of change in each
WIQ score with CVD mortality. For example, we had
only 44% power to observe a statistically significant
association of 2-year change in WIQ distance score with
eed Score
Category 3
ne <5.0 and Increase
.0 Points (n  60)
Category 4
Increase 5.0–20.0
Points (n  125)
Category 5
Increase >20.0
Points (n  52)
p for
Trend
73.19 7.82 73.26 8.18 72.06 8.57 0.54
46.02 67.00 53.85 0.80
14.16 11.00 28.85 0.14
0.65 0.15 0.66 0.16 0.64 0.16 0.23
27.88 5.40 27.94 4.69 27.26 4.31 0.57
16.81 21.00 11.54 0.99
30.97 34.00 13.46 0.19
23.89 21.00 17.31 0.84
20.35 25.00 32.69 0.16
11.50 12.00 13.46 0.21
33.63 30.00 21.15 0.28
8.85 17.00 19.23 0.43
34.51 30.00 32.69 0.83
28.08 35.26 30.61 48.80 32.40 43.51 0.06
45.13 34.00 42.31 0.19
26.55 29.00 25.00 0.52
cross the categories. Two-year WIQ domain score change was calculated by subtracting the 2-year
angiotensin-converting enzyme; BMI  body mass index; CHF  congestive heart failure; MI IQ Sp
Decli
<5
 SDs aCVD mortality.
bing sc
 haza
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ment for newly diagnosed stroke, MI, or angina, or
progression of the ABI, the observed associations of
greater 2-year declines in WIQ domain scores with
higher all-cause mortality were attenuated. These find-
ings suggested that progression of systemic CVD might
explain associations of change in WIQ domain scores
with all-cause mortality.
Relatively little is known regarding the association of
decline in patient-perceived walking ability with mortality
risk in either the PAD population or the general population.
In a population of 7,700 Veterans Administration outpa-
tients, Fan et al. (14) found that a 1-year decrease in the
physical component summary (PCS) score from the Short
Form 36 Health Survey, a global measure of health-related
Adjusted Associations of Categories of 2-Year Change in WIQ StairWith All-Cau e and CVD Mortality Among PAD Participa ts (n  43Table 2 Adjusted Associati ns of Catego ies of 2-Year ChangeWith All-Cause and CVD Mortality Among PAD Particip
Category
All-Cause Mortali
Events HR (95% CI)
P
Category 1 (decline 20.0 points) 34 1.93 (1.01–3.68)
Category 2 (decline 20.0–5.0 points) 20 1.05 (0.54–2.06)
Category 3 (decline 5.0 and increase
5.0 points)
35 0.90 (0.50–1.62)
Category 4 (increase 5.0–20.0 points) 11 0.59 (0.28–1.27)
Category 5 (increase 20.0 points) 22 1.00 (referent)
Category 1 (decline 20.0 points) 31 1.82 (0.94–3.52)
Category 2 (decline 20.0–5.0 points) 20 1.00 (0.51–1.96)
Category 3 (decline 5.0 and increase
5.0 points)
33 0.81 (0.44–1.47)
Category 4 (increase 5.0–20.0 points) 11 0.58 (0.27–1.25)
Category 5 (increase 20.0 points) 22 1.00 (referent)
Category 1 (decline 20.0 points) 28 1.62 (0.80–3.30)
Category 2 (decline 20.0–5.0 points) 18 0.95 (0.45–2.02)
Category 3 (decline 5.0 and increase
5.0 points)
26 0.78 (0.40–1.53)
Category 4 (increase 5.0–20.0 points) 11 0.78 (0.35–1.75)
Category 5 (increase 20.0 points) 17 1.00 (referent)
Category 1 (decline 20.0 points) 28 1.53 (0.75–3.10)
Category 2 (decline 20.0–5.0 points) 18 0.94 (0.45–1.98)
Category 3 (decline 5.0 and increase
5.0 points)
26 0.78 (0.40–1.53)
Category 4 (increase 5.0–20.0 points) 11 0.72 (0.32–1.62)
Category 5 (increase 20.0 points) 17 1.00 (referent)
Category 1 (decline 20.0 points) 27 1.46 (0.72–2.98)
Category 2 (decline 20.0–5.0 points) 18 0.93 (0.44–1.96)
Category 3 (decline 5.0 and increase
5.0 points)
26 0.78 (0.40–1.53)
Category 4 (increase 5.0–20.0 points) 11 0.72 (0.32–1.61)
Category 5 (increase 20.0 points) 17 1.00 (referent)
Model I is adjusted for age, sex, race, bodymass index, smoking status, ankle brachial index, comor
Pair-wise p value shows statistical significance relative to Category 5. Categories for WIQ stair clim
respective WIQ stair climbing score. CI  confidence interval; CVD  cardiovascular disease; HRquality of life that also assesses patient-perceived walkingability, was associated with an increased risk of death (odds
ratio: 2.3, 95% CI: 1.6 to 3.4). Similar findings were
observed by Otero-Rodriguez et al. (15) in a smaller study
of approximately 2,400 Spanish subjects 60 years of age; a
2-year decline in the PCS score predicted all-cause mortal-
ity in the subsequent 4 years of follow-up. Participants with
the greatest decline in PCS score had an HR of 2.12 (95%
CI: 1.39 to 3.24) for mortality. Although the prevalences of
PAD in these study populations were not reported, the
observed associations of declines in patient-perceived walk-
ing ability with mortality are relevant in the PAD popula-
tion. To our knowledge, this is the first study that assessed
the association between decline in patient-perceived walk-
ing ability and all-cause and CVD mortality specifically in
subjects with PAD, who are at higher risk of CVD events
bing ScoreIQ Stair Climbing Score
(n  438)
CVD Mortality
e p
Trend Events HR (95% CI)
Pairwise
p Value
p
Trend
Model I
0.004 15 1.61 (0.59–4.36) 0.350 0.229
7 0.65 (0.22–1.89) 0.430
11 0.43 (0.16–1.18) 0.100
3 0.22 (0.06–0.90) 0.035
10 1.00 (referent) NA
Model I  2-Yr Change in ABI
0.019 15 1.68 (0.62–4.60) 0.310 0.150
7 0.64 (0.22–1.86) 0.411
11 0.41 (0.15–1.13) 0.084
3 0.22 (0.05–0.90) 0.035
10 1.00 (referent) NA
Model I  2-Yr Incident Stroke
0.072 12 1.00 (0.33–2.98) 0.998 0.796
6 0.53 (0.16–1.74) 0.296
7 0.32 (0.10–1.00) 0.050
3 0.29 (0.07–1.27) 0.102
8 1.00 (referent) NA
Model I  2-Yr Incident MI
0.098 12 0.98 (0.34–2.84) 0.973 0.872
6 0.56 (0.17–1.83) 0.337
7 0.31 (0.10–0.96) 0.043
3 0.23 (0.05–0.97) 0.045
8 1.00 (referent) NA
Model I  2-Yr Incident Angina
0.133 12 0.96 (0.33–2.80) 0.940 0.834
6 0.53 (0.17–1.73) 0.295
7 0.30 (0.09–0.95) 0.040
3 0.23 (0.05–0.99) 0.048
8 1.00 (referent) NA
, physical activity, statin use, ACE inhibitor use, study cohort, and baselineWIQ stair climbing score.
ore change were calculated by subtracting the 2-year WIQ stair climbing score from the baseline
rd ratio; other abbreviations as in Table 1.Clim8)in W
ants
ty
airwis
Value
0.05
0.88
0.72
0.18
NA
0.07
0.99
0.48
0.16
NA
0.18
0.90
0.46
0.55
NA
0.24
0.87
0.47
0.43
NA
0.30
0.85
0.47
0.42
NA
biditiesand mortality than subjects without PAD (16).
score c
1827JACC Vol. 61, No. 17, 2013 Jain et al.
April 30, 2013:1820–9 Walking Impairment Score and PAD MortalityWe previously reported that among participants with
PAD in our WALCS cohort, greater 2-year declines in
6-min walking distance and 4-m walking velocity (fast-
paced) were associated with higher all-cause mortality.
Greater 2-year decline in 6-min walking distance was
associated with higher CVD mortality (16). Although
both the 6-min walking distance and 4-m walking
velocity are useful in mortality risk prediction, they are
objective measures that require dedicated time and space
in the clinical setting, whereas the WIQ can be self-
administered by PAD patients and is not time or labor
intensive. However, applying our results to clinical prac-
tice would require that physicians be prompted to re-
administer the WIQ score 2 years after a baseline
measure. Further study is needed to determine whether
Adjusted Associations of Categories of 2-Year Change in WIQ DistaWith All-Cau e and CVD Mortality Among PAD Participa ts (n  43Table 3 Adjusted Associati ns of Catego ies of 2-Year ChangeWith All-Cause and CVD Mortality Among PAD Particip
Category
All-Cause Mortalit
Events HR (95% CI)
P
p
Category 1 (decline 20.0 points) 36 2.34 (1.15–4.75)
Category 2 (decline 20.0–5.0 points) 21 1.68 (0.82–3.43)
Category 3 (decline 5.0 and increase
5.0 points)
29 1.10 (0.57–2.12)
Category 4 (increase 5.0–20.0 points) 18 1.28 (0.62–2.62)
Category 5 (increase 20.0 points) 15 1.00 (referent)
Category 1 (decline 20.0 points) 32 1.91 (0.92–3.96)
Category 2 (decline 20.0–5.0 points) 21 1.52 (0.73–3.13)
Category 3 (decline 5.0 and increase
5.0 points)
28 0.99 (0.50–1.94)
Category 4 (increase 5.0–20.0 points) 18 1.21 (0.59–2.51)
Category 5 (increase 20.0 points) 15 1.00 (referent)
Category 1 (decline 20.0 points) 30 1.42 (0.64–3.18)
Category 2 (decline 20.0–5.0 points) 17 1.26 (0.56–2.84)
Category 3 (decline 5.0 and increase
5.0 points)
25 1.17 (0.55–2.52)
Category 4 (increase 5.0–20.0 points) 14 1.12 (0.50–2.54)
Category 5 (increase 20.0 points) 12 1.00 (referent)
Category 1 (decline 20.0 points) 30 1.57 (0.70–3.48)
Category 2 (decline 20.0–5.0 points) 17 1.22 (0.54–2.74)
Category 3 (decline 5.0 and increase
5.0 points)
25 1.10 (0.52–2.36)
Category 4 (increase 5.0–20.0 points) 15 1.15 (0.51–2.60)
Category 5 (increase 20.0 points) 12 1.00 (referent)
Category 1 (decline 20.0 points) 29 1.49 (0.67–3.31)
Category 2 (decline 20.0–5.0 points) 17 1.21 (0.54–2.72)
Category 3 (decline 5.0 and increase
5.0 points)
25 1.13 (0.53–2.42)
Category 4 (increase 5.0–20.0 points) 14 1.15 (0.51–2.63)
Category 5 (increase 20.0 points) 12 1.00 (referent)
Model I is adjusted for age, sex, race, body mass index, smoking status, ankle brachial index, com
Pair-wise p value shows statistical significance relative to Category 5. Categories for WIQ distance
WIQ distance score. Abbreviations as in Tables 1 and 2.implementing measurement of 2-year change in WIQscores in clinical practice is associated with improved
outcomes.
Study limitations. First, although we adjusted for confound-
ers including comorbidities and baseline WIQ scores, we could
not rule out the possibility that unidentified characteristics
among participants with greater 2-year decline in WIQ do-
main scores contributed to the observed associations with
mortality risk. Second, although measuring 2-year change in
the WIQ allowed us to maximize identification of patients
with meaningful changes in the WIQ score, further study is
needed to determine whether changes in the WIQ score at
shorter follow-up intervals are associated with similar out-
comes to those reported here. However, it is likely that the
magnitude of change in the WIQ score, rather than the length
of time between a baseline and WIQ score, is most important
ScoreIQ Distance Score
(n  431)
CVD Mortality
p Trend Events HR (95% CI)
Pairwise
p Value p Trend
Model I
0.006 13 4.56 (1.30–16.01) 0.018 0.069
11 4.31 (1.26–14.80) 0.020
11 1.32 (0.39–4.50) 0.658
5 1.73 (0.44–6.76) 0.429
4 1.00 (referent) NA
Model I  2-Yr Change in ABI
0.060 13 3.80 (1.09–13.28) 0.036 0.087
11 3.46 (1.00–11.94) 0.050
11 1.09 (0.32–3.73) 0.892
5 1.42 (0.36–5.61) 0.615
4 1.00 (referent) NA
Model I  2-Yr Incident Stroke
0.45 12 1.25 (0.35–4.52) 0.734 0.972
8 1.53 (0.41–5.66) 0.527
8 0.65 (0.16–2.60) 0.540
3 0.62 (0.13–3.06) 0.561
4 1.00 (referent) NA
Model I  2-Yr Incident MI
0.293 12 1.83 (0.51–6.59) 0.355 0.564
8 1.43 (0.38–5.40) 0.594
8 0.59 (0.15–2.31) 0.445
3 0.70 (0.14–3.40) 0.656
4 1.00 (referent) NA
Model I  2-Yr Incident Angina
0.360 12 1.82 (0.50–6.67) 0.363 0.564
8 1.41 (0.38–5.26) 0.612
8 0.53 (0.13–2.09) 0.362
3 0.67 (0.14–3.25) 0.618
4 1.00 (referent) NA
ies, physical activity, statin use, ACE inhibitor use, study cohort, and baseline WIQ distance score.
hange were calculated by subtracting the 2–year WIQ distance score from the baseline respectivence1)in W
ants
y
airwise
Value
0.018
0.158
0.775
0.507
NA
0.081
0.261
0.968
0.605
NA
0.391
0.571
0.679
0.779
NA
0.271
0.635
0.802
0.743
NA
0.332
0.645
0.746
0.736
NA
orbiditwith regard to subsequent outcomes. Third, because we ex-
ore cha
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Walking Impairment Score and PAD Mortality April 30, 2013:1820–9cluded persons who were not fluent in English, who died
before 2-year follow-up, or who underwent lower extremity
revascularization before 2-year follow-up, these findings might
not be generalizable to all PAD patients. Fourth, because of
the relatively small absolute number of events and relatively
large variance in WIQ score changes, 95% CIs were wide.
Fifth, we did not record information about recruitment site.
Thus, we were unable to adjust for recruitment site in our
analyses. However, recruiting consecutive PAD patients from
several noninvasive vascula laboratories in the Chicago area is
likely to increase the generalizability of our findings. There is
no reason to believe that relationships between change in the
WIQ score and mortality would differ between recruitment
sites.
Conclusions
Men and women with PAD with greater decline in WIQ
Adjusted Associations of Categories of 2-Year Change in WIQ SpeeWith All-Cau e and CVD Mortality Among PAD Participa ts (n  43Table 4 Adjusted Associati ns of Catego ies of 2-Year ChangeWith All-Cause and CVD Mortality Among PAD Particip
Category
All-Cause
Events HR (95% CI)
Category 1 (decline 20.0 points) 26 3.55 (1.57–8.0
Category 2 (decline 20.0–5.0 points) 34 2.53 (1.20–5.3
Category 3 (decline 5.0 and increase 5.0 points) 27 1.23 (0.60–2.5
Category 4 (increase 5.0–20.0 points) 22 1.28 (0.61–2.7
Category 5 (increase 20.0 points) 12 1.00 (referent)
Category 1 (decline 20.0 points) 23 2.90 (1.26–6.6
Category 2 (decline 20.0–5.0 points) 34 2.39 (1.13–5.0
Category 3 (decline 5.0 and increase 5.0 points) 26 1.20 (0.58–2.4
Category 4 (increase 5.0–20.0 points) 22 1.26 (0.59–2.6
Category 5 (increase 20.0 points) 12 1.00 (referent)
Category 1 (decline 20.0 points) 21 2.22 (0.89–5.5
Category 2 (decline 20.0–5.0 points) 28 1.91 (0.85–4.2
Category 3 (decline 5.0 and increase 5.0 points) 22 1.09 (0.50–2.3
Category 4 (increase 5.0–20.0 points) 18 1.10 (0.49–2.5
Category 5 (increase 20.0 points) 11 1.00 (referent)
Category 1 (decline 20.0 points) 21 2.31 (0.93–5.7
Category 2 (decline 20.0–5.0 points) 28 1.94 (0.87–4.3
Category 3 (decline 5.0 and increase 5.0 points) 22 1.11 (0.51–2.4
Category 4 (increase 5.0–20.0 points) 18 1.13 (0.50–2.5
Category 5 (increase 20.0 points) 11 1.00 (referent)
Category 1 (decline 20.0 points) 20 2.14 (0.85–5.4
Category 2 (decline 20.0–5.0 points) 28 1.92 (0.86–4.3
Category 3 (decline 5.0 and increase 5.0 points) 22 1.12 (0.51–2.4
Category 4 (increase 5.0–20.0 points) 18 1.14 (0.50–2.5
Category 5 (increase 20.0 points) 11 1.00 (referent)
Model I is adjusted for age, sex, race, body mass index, smoking status, ankle brachial index, co
Pair-wise p value shows statistical significance relative to Category 5. Categories for WIQ speed sc
speed score. Abbreviations as in Tables 1 and 2.stair climbing, WIQ distance, or WIQ speed scores are athigher all-cause mortality risk compared with those with
greater improvement in WIQ domain scores. The progres-
sion of systemic CVD is a potential mechanism for in-
creased all-cause mortality risk.
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